IMU

4.00%

4.8¢ imugene limited

"Many have zero understanding of Biotechnology...

First 1364 Last

Share
Profile

Follow
SENARIS

2,922 Posts.

132

23/06/23

15:07

Post #: 68440183
Share

Originally posted by Taureanbull: ↑

After some ball rubbing today, I’ll have a crack which may or may not age well going forward. But my thoughts are.

IMU has/had 26,000 retail shareholders holding less than 100k each. With only 5 more trading days for tax loss selling , it’s time to dump. What we don’t know is what the average buy in price was for these 26,000 holders. What is certain is they have less that $8900.00 in the game. So they stand to write off a collective fortune if they bought up as far as .62.

Also looking at the influx of new posters many of whom appear to have an interest in biotechs, we are having a change of guard. The new buyers are seeing opportunities. A few have stated they can’t believe they can now buy in at these levels.

By my estimates we have 6 weeks to go until next Vaccinia update from Cohort 4. And a CheckVax update must be getting closer all the time.

After something like 40 good positive price sensitive announcement in a row, I’m not looking for some disaster to be announced by Management.

Occams Razor says the first place to look for the cause of a problem is the most obvious cause. Before wasting time searching for other possibilities.

After reading thousands of posts here on HC the obvious place to look is the people writing the posts. Many have zero understanding of Biotechnology investment. Have little if any understanding of what IMU is actually doing. Many don’t listen or understand the company announcements or listen to the clearly explained information from the CEO or highly credentialed scientists such as Prof’s Fong and Priceman.

It’s also. A common theme for posters to complain they need to be “thrown a bone “ by management to settle their anxiety. Often literally one day after great news. Such as MAST Vaccinia trial moving into Cohort 4 because Cohort 3 was successfully cleared.

Now we have many of the retail 26,000 holders dumping in fear. Unfortunately IMU has had difficulty attracting Institutional Money at a scale to protect its Shareprice. Of course we all know the ASX is not littered with institutional investors that have the ability to even analyse a Biotech. Let alone invest in one. With critical minerals in a super boom why would they chase a cancer cure.

Luckily for us, PH has fired the starters gun for a Nasdaq Listing where they do have a sophisticated abundance of investors for quality biotechs.

My balls are telling me this will turn once the amateurs have been well and truly skinned.

Expand

"Many have zero understanding of Biotechnology investment"

...those that appear to have the most understanding have been spruiking this as a BUY whilst in the 50s, 40s 30s..

IMU Price at posting: 8.9¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 418 more messages in this thread...

First 1364 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change -0.002(4.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.7¢	$2.298M	47.86M

Buyers (Bids)

No.	Vol.	Price($)
5	1925982	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	3452098	12

View Market Depth

No.	Vol.	Price($)
5	1925982	0.048
33	4297134	0.047
47	3841303	0.046
53	6064000	0.045
11	2329545	0.044

Price($)	Vol.	No.
0.049	2620667	8
0.050	2639213	14
0.051	6431004	11
0.052	2071350	7
0.053	418882	5

Last trade - 16.10pm 27/09/2024 (20 minute delay)

IMU (ASX) Chart

"Many have zero understanding of Biotechnology...

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

"Many have zero understanding of Biotechnology...

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News